LABORATORY CORPORATION OF AMERICA HOLDINGS

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.